Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading expertise in developing and commercializing innovative immune medicines Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotech ...

ISerg Turnaround plays can be highly rewarding for investors willing to go against the grain. This includes names that for one reason or another have been beaten down in price by the market due to perceived risks or memories of management missteps in the past. One such example that I can think of its Kinder Morgan (KMI), which judging by readers' comments, still carries a bad taste after its dividend cut from years ago despite solid and growing operating fundamentals, reasonably low valuation, and divid ...

Bristol-Myer Squibb Company (NYSE:BMY) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Geoff Meacham - Bank of Ameri ...

For the quarter ended March 2024, Bristol Myers Squibb (BMY) reported revenue of $11.87 billion, up 4.7% over the same period last year. EPS came in at -$4.40, compared to $2.05 in the year-ago quarter.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a cru ...

Bristol-Myers Squibb Company (BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.The year-over-year deterioration can be attributed to higher acquired IPRD costs, reflecting the impact of recent acquisitions and an increase in operating expenses.  The bottom-line was also negatively impacted due to higher interest expenses resulting from new debt issuance to fund ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number 001-01136 ___________________________ BRISTOL-MYERS SQUIBB COMPANY (Exac ...

Investors didn't like the biopharmaceutical company's updated guidance.Shares of Bristol Myers Squibb (BMY -7.89%) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its first-quarter results before the market opened.Bristol Myers Squibb reported Q1 revenue of $11.9 billion, up 5% year over year. The company posted a loss of $5.89 per share based on generally accepted accounting principles (GAAP) compared to a profit of $1.07 per share in the prior-year perio ...

Bristol-Myers Squibb (NYSE:BMY) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce.Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs. The company is expecting this will save it $1.5 billion per year by 2025.These job cuts come after the company completed recent acquisition of Karuna and RayzeBio. It’s also worth mentioning that Bristol-Myers Squibb’s Q1 earnings repor ...

For the quarter ended March 2024, Bristol Myers Squibb (BMY) reported revenue of $11.87 billion, up 4.7% over the same period last year. EPS came in at -$5.89, compared to $2.05 in the year-ago quarter.The reported revenue represents a surprise of +3.57% over the Zacks Consensus Estimate of $11.46 billion. With the consensus EPS estimate being -$4.55, the EPS surprise was -29.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile • First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange) ◦ Growth Portfolio Revenues were $4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) • Strengthened Long-Term Growth Profile Through Completion of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune Transacti ...